Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Key Highlights
- ➤John Harlow appointed President and Chief Operating Officer of Larimar (LRMR)
- ➤800,000-share stock option awarded to Harlow at grant-date closing price
- ➤50,000-share restricted stock unit award granted to Harlow
- ➤Option vests over four years; RSUs vest in four annual installments
- ➤Nomlabofusp advances toward potential approval for Friedreich’s ataxia
Expert Statements
Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar Therapeutics
“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team. His commercial and operational leadership, coupled with his proven ability to translate strategy into execution, will be instrumental as we scale the organization and prepare to bring nomlabofusp to patients worldwide.”
John Harlow, President and Chief Operating Officer of Larimar Therapeutics
“Larimar has a unique opportunity to deliver the first potential disease-modifying therapy for adults and pediatric patients living with Friedreich’s ataxia. I look forward to working with Carole and this talented team to deliver a successful launch and position the company for long-term growth.”
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.
“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar. “His commercial and operational leadership, coupled with his proven ability to translate strategy into execution, will be instrumental as we scale the organization and prepare to bring nomlabofusp to patients worldwide.”
Get started
Create a free account to read the full story.